Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 in Moderate to Severe Plaque Psoriasis
NCT07724366Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 3 trial of TQH3906 in plaque psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Sep 2026; status: recruiting.
02
Drugs
TQH3906
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07724366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724366.